Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic Value of Pretreatment Lymphocyte-to-monocyte Ratio in Patients With in Non-metastatic Renal Cell Carcinoma: a Systematic Review and Meta-analysis

NCT04213664 is registered in ClinicalTrials.gov with Corporacion Parc Tauli as lead sponsor.

NCT NCT04213664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04213664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic Value of Pretreatment Lymphocyte-to-monocyte Ratio in Patients With in Non-metastatic Renal Cell Carcinoma: a Systematic Review and Meta-analysis
Lead sponsor
Corporacion Parc Tauli
Phase
Observational
Overall status
Unknown status
Start date
December 31, 2019
Completion date
January 31, 2020
Enrollment
4,666 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

local disease, lymphocyte disorder, monocytosis, progression, renal cell carcinoma